Search
Glioblastoma Clinical Trials
A listing of 93 Glioblastoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
37 - 48 of 93
There are currently 93 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Glioblastoma participants are California, Ohio, New York and Pennsylvania.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Short Course Radiotherapy for the Treatment of Patients with Glioblastoma, SAGA Study
Recruiting
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter per... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +7 locations
Conditions: Glioblastoma
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
Recruiting
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Maryland Proton Treatment Center, Baltimore, Maryland +4 locations
Conditions: Glioma, Glioblastoma, Brain Tumor
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Recruiting
This is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 component (subdivided into Arms A - C), and an expansion Phase 1b. Patients with tumors demonstrating a positive PK response in the Phase 0 component of the study will be eligible to graduate to an expansion phase that combin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Glioblastoma, Glioma, Glioblastoma Multiforme, Glioma, Malignant
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Recruiting
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Glioblastoma
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Recruiting
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.
The name of the study drug involved in this research study is:
-Troriluzole (a tripeptide prodrug of riluzole)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Recruiting
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors.
The central clinical... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/05/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia +4 locations
Conditions: Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Recruiting
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity.
GCC2020 is... Read More
Gender:
ALL
Ages:
Between 6 years and 25 years
Trial Updated:
03/05/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia
Conditions: Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
Recruiting
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion. Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Recruiting
This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent).
Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Glioblastoma, Recurrent Glioblastoma
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
Recruiting
This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Glioblastoma
Assessment of Optune Therapy for Patients with Newly Diagnosed Glioblastoma Using Advanced MRI
Recruiting
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/22/2025
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Glioblastoma
Methimazole in Patients With Progressive Glioblastoma
Recruiting
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Glioma
37 - 48 of 93